{"analyses":[{"ciLowerLimit":"0.821","ciNumSides":"TWO_SIDED","ciPctValue":"80","ciUpperLimit":"1.370","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.384","pValueComment":"Stratified by pre-specified randomization stratification factors: 1 - 3 prior therapies vs. 4-6 prior therapies and refractory to bortezomib vs. not refractory to bortezomib.","paramType":"Hazard Ratio (HR)","paramValue":"1.061","statisticalComment":"One-sided stratified log rank test","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4","upperLimit":"11","value":"5"},{"groupId":"OG001","lowerLimit":"6","upperLimit":"12","value":"8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"57"}],"units":"Participants"}],"description":"Assessed in each arm using the method of Kaplan Meier and compared between arms using the stratified long-rank test. Progression is defined using the International Uniform Response Criteria for Multiple Myeloma as new or increase in size of existing bone lesions or soft tissue plasmacytomas; or development of hypercalcemia attributable solely to MM; or ≥ 25% increase from baseline or lowest response level of either serum M protein, urine M protein, difference in involved \\& uninvolved serum free light chain level or bone marrow plasma cell percentage.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive 20 mg dexamethasone IV and low-dose (27 mg/m\\^2) carfilzomib IV over 2-10 minutes on days 1, 2, 8, 9, 15, and 16. (Note that course 1 is given at a reduced dose of 20 mg/m\\^2.) Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Patients with progression cross-over to Arm II.\n\nCarfilzomib: Given IV\n\nDexamethasone: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies","id":"OG000","title":"Arm I (Dexamethasone, Low-dose Carfilzomib)"},{"description":"Patients receive 20 mg dexamethasone IV and high-dose (56 mg/m\\^2) carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16. (Note that course 1 is given at a reduced dose of 20 mg/m\\^2 over 2-10 minutes.) Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.\n\nCarfilzomib: Given IV\n\nDexamethasone: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies","id":"OG001","title":"Arm II (Dexamethasone, High-dose Carfilzomib)"}],"paramType":"MEDIAN","populationDescription":"Group of participants that were eligible and analyzable per protocol.","reportingStatus":"POSTED","timeFrame":"From date of registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause, assessed up to 2 years","title":"Progression-free Survival","type":"PRIMARY","unitOfMeasure":"months"}